Ocular Therapeutix Inc (NASDAQ: OCUL) kicked off on Tuesday, down -6.17% from the previous trading day, before settling in for the closing price of $7.94. Over the past 52 weeks, OCUL has traded in a range of $4.06-$11.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 100.53% over the past five years. While this was happening, its average annual earnings per share was recorded 0.73%. With a float of $133.91 million, this company’s outstanding shares have now reached $157.75 million.
Let’s look at the performance matrix of the company that is accounted for 274 employees. In terms of profitability, gross margin is 91.16%, operating margin of -269.83%, and the pretax margin is -303.95%.
Ocular Therapeutix Inc (OCUL) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ocular Therapeutix Inc is 15.79%, while institutional ownership is 72.51%. The most recent insider transaction that took place on Feb 24 ’25, was worth 147,533. In this transaction an insider of this company sold 21,475 shares at a rate of $6.87, taking the stock ownership to the 3,520,318 shares. Before that another transaction happened on Feb 24 ’25, when Company’s Chief Scientific Officer sold 3,061 for $6.87, making the entire transaction worth $21,029. This insider now owns 265,998 shares in total.
Ocular Therapeutix Inc (OCUL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 0.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.84% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Take a look at Ocular Therapeutix Inc’s (OCUL) current performance indicators. Last quarter, stock had a quick ratio of 10.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.29 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Ocular Therapeutix Inc (NASDAQ: OCUL) saw its 5-day average volume 1.65 million, a positive change from its year-to-date volume of 1.19 million. As of the previous 9 days, the stock’s Stochastic %D was 48.81%. Additionally, its Average True Range was 0.53.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 27.80%, which indicates a significant decrease from 53.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.39% in the past 14 days, which was higher than the 61.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.69, while its 200-day Moving Average is $8.33. Nevertheless, the first resistance level for the watch stands at $7.99 in the near term. At $8.52, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.80. If the price goes on to break the first support level at $7.18, it is likely to go to the next support level at $6.90. Assuming the price breaks the second support level, the third support level stands at $6.37.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
The company with the Market Capitalisation of 1.18 billion has total of 159,022K Shares Outstanding. Its annual sales at the moment are 63,720 K in contrast with the sum of -193,510 K annual income. Company’s last quarter sales were recorded 17,080 K and last quarter income was -48,390 K.
